MRKR

Business Context and Reporting Period

Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company developing non-engineered, multi tumor-associated antigen (multiTAA)-specific T cell therapies for hematological malignancies and solid tumors. This Form 10-Q covers the quarterly period ended September 30, 2024. The Company is classified as a non-accelerated filer and a smaller reporting company. As of November 7, 2024, there were 8,923,490 shares of common stock outstanding.

Key Financial Metrics

Note: Revenue consists entirely of grant income. There were no revenues from product sales or licensing.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 647% in Q3 2024 compared to Q3 2023, driven primarily by the recognition of $0.7 million in grant income from a new NIH SBIR grant for MT-601 (NHL) and continued recognition from CPRIT and FDA grants.
• Operating Expenses:
  • R&D: Increased 70% to $3.47 million in Q3 2024, primarily due to a $0.9 million increase in outsourced clinical manufacturing costs with Cell Ready and a $0.9 million increase in clinical trial expenses.
  • G&A: Decreased 39% to $0.85 million in Q3 2024, driven by reductions in consulting expenses, headcount-related costs, and legal fees.
• Net Loss Improvement: The net loss from continuing operations narrowed by 23% in Q3 2024 compared to the prior year, attributed to higher grant income and reduced G&A expenses.
• Discontinued Operations: The Company had no activity related to discontinued operations in 2024. In 2023, the sale of manufacturing assets to Cell Ready resulted in a gain of approximately $8.8 million, which is not present in the current period.

Guidance, Outlook, and Risks

• Liquidity and Runway: Management anticipates that current cash and cash equivalents ($9.0 million), combined with anticipated drawdowns of available grant funds, will fund operating expenses and capital requirements into October 2025. This estimate is subject to the Company's ability to manage costs and secure additional capital.
• Going Concern: The filing explicitly states that the Company's lack of sufficient revenue sources to sustain future operations raises substantial doubt regarding its ability to continue as a going concern. The financial statements are prepared on a going concern basis without adjustments for potential asset recoverability issues.
• Capital Markets: The Company terminated its ATM Agreement with Cantor Fitzgerald and RBC Capital Markets in June 2024 and is currently exploring more effective ways to access equity markets. It also terminated a Stock Purchase Agreement with Lincoln Park in March 2024.
• Related Party Transactions: The Company relies heavily on Cell Ready, LLC (owned by a director/shareholder) for manufacturing and R&D services under a Master Services Agreement. Related party expenses totaled $3.1 million for the nine months ended September 30, 2024.
• Grant Dependency: Future operations are heavily dependent on the successful drawdown of government grants (CPRIT, FDA, NIH SBIR). Delays in funding or failure to meet grant milestones could materially impact liquidity.

Investor Verification Checklist

• Grant Funding Status: Verify the actual receipt of cash from the NIH SBIR, CPRIT, and FDA grants mentioned as receivables or anticipated drawdowns.
• Related Party Costs: Review the Master Services Agreement with Cell Ready to understand the pricing structure and long-term financial commitment for outsourced manufacturing.
• Capital Raising Strategy: Monitor announcements regarding new financing mechanisms following the termination of the ATM and Lincoln Park agreements.
• Cash Burn Rate: Track the monthly cash burn rate to validate the management's projection of funding runway into October 2025.
• Clinical Progress: Confirm the status of the APOLLO study and other clinical trials for MT-601 and MT-401, as these drive future grant eligibility and potential commercialization.